USA), levofloxacin and the novel ketolide, HMR 3647 (Hoechst Marion Roussel, France), the oxazolidinone, linezolid (Pharmacia and Upjohn, Kalamazoo, MI, USA), and trovafloxacin and azithromycin (Pfizer, Groton, CT, USA). MICs were determined by an agar dilution method recommended by the National Committee for Clinical Laboratory Standards. 3 The medium used was MuellerHinton agar (Difco, Detroit, MI, USA) supplemented with 5% sheep blood, and inocula of 10 4 cfu were delivered to the surfaces of the plates with a Steers replicator. S. pneumoniae ATCC 6305 and ATCC 40619 were included as controls.
The in-vitro activities of the 11 antibiotics against the 75 isolates are shown in the Table. Most of the penicillinsusceptible isolates were susceptible to all of the antibiotics tested, the exception being ciprofloxacin to which all but one strain were resistant. Of the 52 isolates exhibiting intermediate susceptibility to penicillin, at least 51 were susceptible to each of the newer fluoroquinolones and linezolid. The susceptibilities of these strains to azithromycin, erythromycin and clindamycin were variable (51.9-86.5%), and only 7.7% and 3.8% were susceptible to cefprozil and ciprofloxacin, respectively. The susceptibility patterns of the penicillin-resistant isolates were broadly similar to those of the strains with intermediate susceptibilities, with the novel fluoroquinolones and linezolid being highly active, the macrolides and clindamycin having variable activities (44.4-100% of isolates being susceptible) and all of the isolates being resistant to cefprozil and ciprofloxacin. As neither validated nor tentative MIC breakpoints for HMR 3647 were available at the time the study was undertaken, susceptibility categories could not be assigned. However, the MICs of this drug are very low (р0.03 mg/L) and it is likely that all of the isolates tested, irrespective of their penicillin susceptibilities, would be regarded as susceptible.
We also determined the MICs of the two macrolides and clindamycin for the study isolates following induction, i.e. after incubation of the strains in the presence of erythromycin at a concentration of 0.5 mg/L, and compared them with those determined without induction. The MICs of all three antibiotics for six of the strains (one penicillinsusceptible and five exhibiting intermediate susceptibility) increased by at least two two-fold dilutions following exposure to erythromycin. These six isolates harboured the ermB gene, which encodes methylation of 23S rRNA, were resistant to both the macrolides and clindamycin, and exhibited inducible resistance. The remaining 22 erythromycinresistant isolates were not phenotypically inducible, exhib- ited variable susceptibilities to penicillin, carried the mefE gene which is thought to encode an efflux pump, and were resistant to the macrolides but not to clindamycin. This is the first study to compare the in-vitro activities of grepafloxacin, levofloxacin, trovafloxacin, linezolid and HMR 3647 against clinical isolates of S. pneumoniae with reduced susceptibilities to penicillin which were recovered in the USA, although the MICs of the quinolones are similar to those reported previously. 4, 5 Other investigators have shown clindamycin to be highly active against pneumococci, but they did not characterize the erythromycin resistance genes carried by the strains. 6 Our results suggest that the newer fluoroquinolones, linezolid and HMR 3647 would provide appropriate empirical therapy of patients with invasive pneumococcal infections, irrespective of their susceptibilities to penicillin.
